FFFelipe Magalhães Furtado

Felipe Magalhães Furtado

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Felipe Magalhães Furtado has a total of 24 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Artificial intelligence‐based screening of paroxysmal nocturnal hemoglobinuria clones: Development and comparative evaluation of machine learning models

    by Felipe Magalhães Furtado, Fernanda de Oliveira Resende, Camila Santos Nobre, Alan Carvalho Dias, André Luiz Pinto, Adamara Felício

    The diagnosis of paroxysmal nocturnal hemoglobinuria (PNH) relies on detecting cells deficient in GPI‐anchored proteins and is currently based on manual, time‐consuming interpretation requiring specialized expertise. This study aimed to develop machine learning models to identify PNH clones in granulocytes and monocytes using flow cytometry data containing information on cell size, complexity, and expression of FLAER, CD15, CD45, CD64, and CD157. For training, 20 normal and 20 PNH samples were randomly selected; normal samples were used in full, whereas only PNH cells were retained from PNH samples. For analytical validation, 22 normal and 18 PNH samples were analyzed in their entirety. Samples were processed through a preprocessing pipeline and split into training (12 normal, 12 PNH), validation (4 normal, 4 PNH), and test (4 normal, 4 PNH) datasets. Two supervised models were developed: a Random Forest (RF) and an Artificial Neural Network (ANN). Validation samples underwent the same preprocessing, except for concatenation. Both models achieved specificity close to 100%, accuracy >93%, ROC‐AUC >0.99, and PR‐AUC >0.98; the ANN showed higher sensitivity (0.85 vs. 0.78) and F1‐score (0.92 vs. 0.87). In qualitative analysis, RF and ANN achieved 100% and 45% agreement with manual analysis, respectively, and quantitative analysis confirmed statistical equivalence between RF and manual results. RF repeatability was confirmed by identical triplicate results in 10 samples. In spiking experiments, RF identified >50 PNH cells in all samples spiked with 200 or 100 cells, in 3 of 5 samples spiked with 50 cells, and in none spiked with 25 cells. These results indicate that the RF model shows promise for PNH analysis; however, clinical implementation will require integration into immunophenotyping software and post‐deployment performance monitoring.

  • Open Access

    Hematopoietic stem cell transplantation for acute myeloid leukemia: Brazilian Society of Cell Therapy and Bone Marrow Transplantation Consensus

    by Mariana Pinto Pereira, Maura Rosane Valério Ikoma-Colturato, Vaneuza Araujo Funke, Beatriz Stela Gomes de Souza Pitombeira, Eduardo José de Alencar Paton, Adriano Arantes, Karine Sampaio Nunes Barroso, Miriam Perlingeiro Beltrame, Gustavo Bettarello, Camila de Pádua Coelho Hugo, et al.

    This document updates the 2023 Brazilian Society of Cell Therapy and Bone Marrow Transplantation (SBTMO) consensus on allogeneic hematopoietic stem cell transplantation (HSCT) for acute myeloid leukemia (AML), incorporating the 2022 and 2024 European LeukemiaNet (ELN) risk classifications, the 2025 ELN-DAVID measurable residual disease (MRD) recommendations, recent induction trials, and the 2025 European Society for Blood and Marrow Transplantation (EBMT) transplant indications. MRD monitoring, assessed by quantitative polymerase chain reaaction, next-generation sequencing, or multiparameter flow cytometry, now guides transplant timing alongside ELN risk category, refining decisions in intermediate-risk patients and informing pre- and post-transplant management. Allogeneic HSCT remains indicated for adverse-risk AML and second complete remission regardless of MRD status, while favorable-risk patients generally avoid transplant unless MRD persists after consolidation. For elderly patients, chronological age alone should not exclude HSCT candidacy; comprehensive geriatric assessment and alternative donor sources have expanded access, supported by Brazilian regulatory changes raising the eligibility age to 75. Conditioning strategy, graft-versus-host disease prophylaxis with post-transplant cyclophosphamide, stem cell source selection, and donor immunogenetic screening are addressed, alongside emerging post-transplant maintenance therapies for high-risk molecular subgroups. Novel cellular therapies— CAR-T and CAR-NK cells—remain investigational, limited by antigen escape and short persistence, requiring consolidation with allogeneic HSCT. This consensus provides evidence-graded recommendations to standardize transplant decisionmaking for AML across Brazilian centers, reflecting the rapidly evolving therapeutic and diagnostic landscape.

  • Open Access

    Minimal residual disease assessment in acute lymphoblastic leukemia by 4-color flow cytometry: Recommendations from the MRD Working Group of the Brazilian Society of Bone Marrow Transplantation

    by Maura R.V. Ikoma-Colturato, Miriam P. Beltrame, Felipe M. Furtado, Glicinia Pimenta, Elaine Sobral da Costa, Ana Paula Azambuja, Mariester Malvezzi, Mihoko Yamamoto